Children
Atazanavir (Reyataz) is only licensed for use in adults.
A phase I / II study of atazanavir in children is underway in the United States. The study, called PACTG 1020A, aims to establish an effective and safe dosage of atazanavir in children. To date, the study has demonstrated that atazanavir clearance depends on the child’s age and is faster in children than in adults. It has also found that atazanavir does not cause significant changes in blood fat levels in children, as in adults[1][2].
latest aidsmap news
- Traditional healers could play key role in ART rollout
- HIV testing for mothers and children must expand, UN report shows
- London hospital to test new HIV vaccine candidate
- Counselling sessions can reduce reported risky sex by HIV-positive gay men
- HIV diagnoses in European MSM have almost doubled since 2000, UK tops the list
- Older HIV-positive gay men as likely to have risky sex as younger gay men with HIV
- Mbeki's opposition to ARVs cost 330,000 lives, shows study
- Universal testing and treatment could reduce new HIV infections in southern Africa by 95% in 10 years
- Record number of people accessing HIV care in the UK
- Treatment during primary HIV infection has limited benefit